# Semaglutide new study: what BioQ data show

> A new FAERS paper on semaglutide and panic attacks, set against ChEMBL potency, ClinicalTrials.gov registrations and PubChem identity as of 2026-11-15.

Data as of 2026-11-15 · Published 2026-11-15 · Updated 2026-11-15 · https://bioq.bio/blog/en/semaglutide-semaglutide-and-panic-attacks-activecomparator-disproportional

![BioQ result page for the query semaglutide, showing ChEMBL potency, ClinicalTrials.gov trials and compound identity](https://bioq.bio/blog/img/semaglutide-semaglutide-and-panic-attacks-activecomparator-disproportional/en/hero.webp)

A new pharmacovigilance paper looks at semaglutide and panic attacks. Today BioQ's public data place semaglutide at one measured ChEMBL target, GLP1R, with a best pChEMBL of 11.21 (EC50, 11 exact measurements), and list 349 registered studies in ClinicalTrials.gov. The paper's results are the paper's own. This page shows only the background data, as of 2026-11-15.

## What we asked about the new semaglutide study

The paper appeared in Pharmacoepidemiology and Drug Safety. It asks whether the reported link between semaglutide and panic attacks in spontaneous adverse-event reports reflects the drug or the way the reports are generated. The authors work with the FDA Adverse Event Reporting System. They compare semaglutide with active comparators (dulaglutide and empagliflozin) rather than with all other drugs. They also test for notoriety bias, meaning more reporting once a drug draws public attention. Finally, they set the signal beside randomized and observational evidence in an evidence-triangulation framework.

We do not restate or check those results here. Reporting odds ratios, confidence intervals and the review findings belong to the paper, and you should read them there.

The question we put to BioQ is narrower. When someone reads this paper, what does the drug look like in public molecular and trial data? We asked three things: which targets have measured potency for semaglutide, how many trials are registered and at what stage, and how the compound is identified across databases.

## What BioQ returned

The query was simply "semaglutide". BioQ drew on three resources: ChEMBL for potency, ClinicalTrials.gov for registered studies, and PubChem for identity.

**Measured potency (ChEMBL).** ChEMBL lists one target for semaglutide (compound CHEMBL2108724), and that target has exact measurements. pChEMBL is the negative log10 of the molar potency.

| ChEMBL target | Gene | Best pChEMBL | Type | Exact measurements |
|---|---|---|---|---|
| CHEMBL1784 | GLP1R | 11.21 | EC50 | 11 |

![BioQ target view for semaglutide listing GLP1R as the measured ChEMBL target with its best pChEMBL value](https://bioq.bio/blog/img/semaglutide-semaglutide-and-panic-attacks-activecomparator-disproportional/en/targets.webp)
*Target view for the query semaglutide in BioQ*

**Registered trials (ClinicalTrials.gov).** The snapshot matches 349 studies with semaglutide as an intervention. Of these, 73 are Phase 1, 68 are Phase 2 and 108 are Phase 3. The table below is only a page of six rows, so it shows the variety of entries and not the whole set.

| Trial | Phase | Status | Sponsor | Start | Enrollment |
|---|---|---|---|---|---|
| NCT02243098 | PHASE1 | COMPLETED | Novo Nordisk A/S | 2014-09 | 31 |
| NCT01572753 | PHASE1 | COMPLETED | Novo Nordisk A/S | 2012-04 | 161 |
| NCT02249871 | PHASE1 | COMPLETED | Novo Nordisk A/S | 2014-09 | 54 |
| NCT07769047 | PHASE4 | NOT_YET_RECRUITING | Mayo Clinic | 2026-09 | 50 |
| NCT06639464 | PHASE2 | RECRUITING | Brigham and Women's Hospital | 2025-06 | 46 |
| NCT04261933 | — | COMPLETED | Novo Nordisk A/S | 2020-02 | 789 |

**Compound identity (PubChem).** The PubChem record is CID 56843331, with InChIKey DLSWIYLPEUIQAV-CCUURXOWSA-N and 22 synonyms. This matters when you match names across pharmacovigilance tables, trial registries and chemistry databases. The PubChem lookup returned no ChEMBL identifier, so the link to CHEMBL2108724 comes from the ChEMBL potency lookup.

The three queries took 0.75 seconds of engine time in total. Doing the same by hand means searching three separate resources, each with its own name matching and export format.

## What it means and how to read it

**The mechanism side.** The one ChEMBL target is GLP1R, the receptor for glucagon-like peptide 1. The measure is an EC50, a functional potency value, so it describes how readily the compound drives receptor activity in an assay. It is not an inhibition constant. A pChEMBL of 11.21 means very high potency in those assays. It tells you about receptor engagement and says nothing about what happens in a patient's mood or anxiety.

That is the main way to place the paper. A disproportionality analysis works from reports of events in people. The ChEMBL data work from assays on a defined molecular target. The two layers answer different questions, and neither one can confirm or rule out a link to panic attacks on its own. What the molecular data do give you is a clear statement of the drug's primary measured target, which is useful when you ask whether a proposed explanation has a biological route.

**The trial side.** The registry holds a large body of studies, spread across Phase 1, Phase 2 and Phase 3. The sample rows show early-phase work sponsored by Novo Nordisk A/S, a completed study with 789 participants, a recruiting Phase 2 study from Brigham and Women's Hospital with 46, and a Phase 4 study from Mayo Clinic that is not yet recruiting, with a planned 50. The paper's evidence-triangulation approach draws on randomized trials, so a registry count shows how much trial material exists in principle. It does not show which trials recorded anxiety or panic outcomes, or how those outcomes were defined.

**Why the identity record matters.** Active-comparator work depends on correct drug names. The synonym count and the stable identifiers in the PubChem record help you check that reports, trials and assay data refer to the same molecule.

## How to reproduce it in BioQ

1. Open BioQ and enter the single-word query shown below.
2. Read the target section first. Check the ChEMBL target, the activity type (EC50) and the number of exact measurements, so you know what kind of potency value you have.
3. Open the trial section and note the phase counts for all matched studies. Then filter or sort the page by status or sponsor if you want a particular subset.
4. Open the compound section to copy the PubChem and ChEMBL identifiers into your own notes or scripts.
5. Every answer names its source, so you can cite ChEMBL, ClinicalTrials.gov and PubChem separately.

```text
semaglutide
```

[Open this query in BioQ](https://bioq.bio/login?next=%2Fapp%23q%3Dsemaglutide)

To go further, run the same query with a comparator name such as dulaglutide or empagliflozin and compare the target and trial sections side by side.

## Limits: what the data do not show

- BioQ does not contain the paper's analysis. The odds ratios, the temporal analyses and the systematic review are the authors' work and are not reproduced or checked here.
- Potency data describe a molecular target, not a clinical outcome. They cannot say whether semaglutide causes or does not cause panic attacks.
- The ChEMBL view shows one target with exact measurements. It does not show every assay that has ever been run, and the absence of other targets here is not proof that none exist.
- The trial registry shows registrations, not results. It does not tell you which studies measured anxiety-related outcomes, and the table is a page of six rows, not the full set of studies.
- Spontaneous reporting data carry their own biases, which is what the paper examines. Nothing here substitutes for reading the paper itself.
- This page gives no medical, dosing or treatment advice.

## Data and method
The numbers on this page were read from the BioQ engine on 2026-11-15 (3 queries, 0.8 s of engine time in total). The tables are generated by code from the engine's answers; the text only restates them.

`/chembl_potency`, `/clinicaltrials`, `/compound`

## Sources
- Semaglutide and Panic Attacks: Active‐Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post‐Marketing Pharmacovigilance (2026) — [doi:10.1002/pds.70517](https://doi.org/10.1002/pds.70517)

Run the same query yourself: [semaglutide](https://bioq.bio/login?next=%2Fapp%23q%3Dsemaglutide)

*For research use only. This page summarises public data and is not medical advice.*

BioQ is an AI search engine and agent with one goal: making biology research 100X faster. Ask in the web app, over the REST API, or from Claude, ChatGPT or Cursor through MCP.

## Queries used

- [`semaglutide`](https://bioq.bio/login?next=%2Fapp%23q%3Dsemaglutide)

## Frequently asked questions

### What does BioQ show as the measured target of semaglutide?

ChEMBL lists one target, GLP1R, with a best pChEMBL of 11.21 from EC50 data and 11 exact measurements, as of 2026-11-15.

### How many semaglutide trials are registered in ClinicalTrials.gov?

The snapshot matches 349 studies, of which 73 are Phase 1, 68 are Phase 2 and 108 are Phase 3.

### Does BioQ confirm the semaglutide and panic attack signal from the new paper?

No. The paper's FAERS results are its own, and BioQ shows only background data on the drug, its target and its trials. Those data cannot confirm or exclude a link to panic attacks.

### How do I find the PubChem and ChEMBL identifiers for semaglutide?

Searching "semaglutide" returns PubChem CID 56843331 with 22 synonyms and the ChEMBL compound CHEMBL2108724 from the potency lookup.

### How long does the semaglutide query take in BioQ?

The three queries across three resources took 0.75 seconds of engine time in total.

## Sources

- Paper: [Semaglutide and Panic Attacks: Active‐Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post‐Marketing Pharmacovigilance](https://doi.org/10.1002/pds.70517) (2026) DOI 10.1002/pds.70517
- Dataset: [ClinicalTrials.gov](https://clinicaltrials.gov/)
- Dataset: [PubChem](https://pubchem.ncbi.nlm.nih.gov/)

> Results come from public databases as of the date shown and may change. BioQ gives research information, not medical advice.
